comparemela.com
Home
Live Updates
ACADIA Pharmaceuticals Sinks After Schizophrenia Drug Failed In Late-stage Study : comparemela.com
ACADIA Pharmaceuticals Sinks After Schizophrenia Drug Failed In Late-stage Study
Shares of ACADIA Pharmaceuticals Inc. (ACAD) are down more than 18 percent in pre-market on Tuesday at $19.71, after its schizophrenia drug candidate failed to meet the primary endpoint in late-stage study.
Related Keywords
,
Pharmaceuticals Inc
,
Negative Symptom
,
comparemela.com © 2020. All Rights Reserved.